Acromegaly: all 203 studies

Page 1 of 3. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.

• PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary TumoursNot yet recruitingNCT07813351Phase 3
• Direct Versus Video Laryngoscopy in Patients With AcromegalyNot yet recruitingNCT07659912
• A Study to Evaluate MAR002 for AcromegalyRecruitingNCT07641179Phase 2
• An Observational Study of Octreotide Subcutaneous Depot in Patients With AcromegalyRecruitingNCT07583563
• Ultrasound in Predicting Difficult Intubation in Acromegaly PatientsNot yet recruitingNCT07306325
• Study of MAR002 in Healthy MenRecruitingNCT07195175Phase 1
• Effects of Pasireotide Lar Therapy on Bone MetabolismRecruitingNCT07179926
• KETOgenic Diet Therapy in Patients With ACROmegalyRecruitingNCT06949891Not applicable
• A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin AnalogsRecruitingNCT06930625Phase 3
• The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In AcromegalyRecruitingNCT06597383
• Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess.RecruitingNCT06344650
• Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical ModelsNot yet recruitingNCT06326853
• Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional StudyRecruitingNCT05964712
• Diet in the Management of AcromegalyRecruitingNCT05401084Not applicable
• Hypoproteic Diet in AcromegalyNot yet recruitingNCT05298891Not applicable
• The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness ResearchRecruitingNCT03158090
• Developing a Simple Recognition System of AcromegalyRecruitingNCT03042026
• Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPARecruitingNCT00461188
• An Investigation of Pituitary Tumors and Related Hypothalmic DisordersRecruitingNCT00001595
• A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)TerminatedNCT05192382Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of AcromegalyTerminatedNCT04837040Phase 3Results posted
• A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With AcromegalyCompletedNCT04522180Phase 2Results posted
• A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyCompletedNCT04076462Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)CompletedNCT03792555Phase 2Results posted
• An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)CompletedNCT03789656Phase 2Results posted
• Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor LigandsCompletedNCT03548415Phase 2Results posted
• Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in AcromegalyStatus unknownNCT03252353Phase 3Results posted
• Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With AcromegalyTerminatedNCT03045302Phase 2Results posted
• Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in AcromegalyCompletedNCT02685709Phase 3Results posted
• Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in AcromegalyCompletedNCT02493517Phase 3Results posted
• Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With AcromegalyCompletedNCT02396953Phase 1/2Results posted
• Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin AnaloguesCompletedNCT02354508Phase 3Results posted
• Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)CompletedNCT02299089Phase 2Results posted
• Clomiphene Citrate for Treatment of AcromegalyCompletedNCT02274311Phase 2Results posted
• Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.CompletedNCT02235987Phase 2Results posted
• The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated AcromegalicsCompletedNCT02217800Phase 2Results posted
• Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyCompletedNCT02060383Phase 4Results posted
• Programme of Acromegaly Screening in Patients With Associated Somatic DisordersCompletedNCT02020967Results posted
• A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.TerminatedNCT01861717Phase 4Results posted
• Ectopic Lipid Deposition and Insulin Resistance in After Treatment of AcromegalyCompletedNCT01819883Results posted
• Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesCompletedNCT01794793Phase 4Results posted
• Acromegaly Treatment Quality of Life StudyCompletedNCT01732406Results posted
• Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary GigantismCompletedNCT01673646Phase 2Results posted
• Acromegaly Combination Treatment StudyTerminatedNCT01538966Not applicableResults posted
• Effects of Sandostatin LAR® in AcromegalyCompletedNCT01424241Phase 4Results posted
• Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for AcromegalyCompletedNCT01412424Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic PatientsCompletedNCT01278342Phase 4Results posted
• Tissue Biomarker for Pegvisomant ActionCompletedNCT01261000Not applicableResults posted
• Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled AcromegalyCompletedNCT01137682Phase 3Results posted
• Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With AcromegalyTerminatedNCT00994214Phase 2Results posted
• Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)CompletedNCT00915954Not applicableResults posted
• Non Interventional Study For Patients Treated With Somavert®CompletedNCT00858143Results posted
• Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic SubjectsCompletedNCT00701363Phase 4Results posted
• Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland MacroadenomaCompletedNCT00690898Phase 3Results posted
• Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment PlanCompletedNCT00658879Results posted
• Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active AcromegalyCompletedNCT00600886Phase 3Results posted
• Ultrasound Guided Octreotide LAR Injection in AcromegalyCompletedNCT00552071Phase 4Results posted
• Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline AutogelCompletedNCT00447499Phase 3Results posted
• Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic PatientsCompletedNCT00383708Phase 3Results posted
• Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled AcromegalyCompletedNCT00372697Phase 3Results posted
• Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone DeficiencyCompletedNCT00182091Not applicableResults posted
• An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With AcromegalyCompletedNCT00171730Phase 2Results posted
• A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With AcromegalyCompletedNCT07814651Phase 2
• A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)CompletedNCT07663318Phase 1
• Ketogenic vs. Mediterranean Diet on Metabolic and Hormonal Parameters in Patients With Active AcromegalyCompletedNCT07100587Not applicable
• ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With AcromegalyTerminatedNCT07037420Phase 2
• Acromegaly Resistant to Conventional Dose of First Generation Somatostatin LigandsCompletedNCT06607666
• A Phase 1 Study of TE-8214 Solution in Healthy VolunteersCompletedNCT06372652Phase 1
• A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and AcromegalyCompletedNCT06253897
• A Single-dose Study of Octreotide Injection in Healthy Adult SubjectsCompletedNCT05761431Phase 1
• Acromegaly: Balance, Falls and Fracture RiskCompletedNCT05752825
• Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in ChinaCompletedNCT05431803
• A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)TerminatedNCT05364944Phase 1
• Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in ChinaWithdrawnNCT05184231
• Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After SurgeryStatus unknownNCT05149495
• Korean Regulatory Post Marketing Surveillance for SomavertCompletedNCT05131100
• PegvisOMant and the Immune SystEm (PROMISE)CompletedNCT05069324
• Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic PatientsStatus unknownNCT04860037
• Vitamin D Metabolism in Patients With Endocrine DisordersCompletedNCT04844164Phase 1
• The TMS Treatment for Postoperative Headache in GH TumorStatus unknownNCT04529356Not applicable
• A Pilot Study of Empagliflozin in the Treatment of Acromegalic CardiomyopathyStatus unknownNCT04520646Not applicable
• Effects of Mindfulness Therapy in Patients With Acromegaly and CushingCompletedNCT04420000Not applicable
• ACRODAT Prospective Evaluation StudyCompletedNCT04349839
• A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)TerminatedNCT04261712Phase 2
• Olfactory Function and Olfactory Bulb Volume in Acromegaly PatientsCompletedNCT04138537Not applicable
• A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyCompletedNCT04125836Phase 3
• Reproducibility and Utility of OGTT in AcromegalyCompletedNCT04066569Not applicable
• Study to Predict Lanreotide-induced Disease Activity Normalization in AcromegalyWithdrawnNCT04003519
• Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor LigandsCompletedNCT03967249Phase 2
• Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788CompletedNCT03849872Phase 1
• Modulating the GIP System in Patients With Acromegaly Due to a Pituitary TumorCompletedNCT03807076Not applicable
• Rehabilitation Program in Patients With AcromegalyStatus unknownNCT03710499Not applicable
• Muscle in Acromegaly and Cushing's SyndromeStatus unknownNCT03673761
• Long Term Outcome Study in Patients With Pituitary DisordersActive, not recruitingNCT03665064
• Acromegaly: Patient And Physician PerspectivesCompletedNCT03613623
• A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult VolunteersTerminatedNCT03571594Phase 1
• Sleep Apnea in Acromegaly After SurgeryStatus unknownNCT03526016
• Seoul National University Pituitary Disease Cohort StudyStatus unknownNCT03474601
• Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary AdenomaStatus unknownNCT03439709Phase 3
• Acromegaly - Before and After TreatmentStatus unknownNCT03431727

← Acromegaly overview